PTC Therapeutics PTCT
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
PTC Therapeutics (PTCT) Core Market Data and Business Metrics
Latest Closing Price
$48.37Price-Earnings Ratio
-8.14Total Outstanding Shares
77.13 Million SharesDividend
No dividendSIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
500 Warren Corporate Center Drive, Warren, NJ, 07059
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 917,404 Shares | 4.69 | 3/14/2025 | 4,302,958 Shares |
| 753,498 Shares | 5.03 | 2/28/2025 | 3,789,596 Shares |
| 858,061 Shares | 4.31 | 2/14/2025 | 3,696,224 Shares |
| 632,430 Shares | 6.58 | 1/31/2025 | 4,161,584 Shares |
| 582,829 Shares | 7.28 | 1/15/2025 | 4,240,687 Shares |
| 530,159 Shares | 7.92 | 12/31/2024 | 4,201,416 Shares |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities, Continuing | $-317.95 Million |
| Net Cash Flow, Continuing | $353.96 Million |
| Net Cash Flow From Financing Activities, Continuing | $849.88 Million |
| Net Cash Flow From Operating Activities, Continuing | $-177.97 Million |
| Net Cash Flow From Operating Activities | $-177.97 Million |
| Net Cash Flow From Investing Activities | $-317.95 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Income/Loss | $-453.20 Million |
| Other Operating Expenses | $211.44 Million |
| Income Tax Expense/Benefit | $27.73 Million |
| Basic Average Shares | $76.94 Million |
| Diluted Earnings Per Share | $-5.94 |
| Operating Income/Loss | $-134.36 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $-467.15 Million |
| Other Comprehensive Income/Loss Attributable To Parent | $-13.95 Million |
| Comprehensive Income/Loss | $-467.15 Million |
| Comprehensive Income/Loss Attributable To Parent | $-467.15 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Current Liabilities | $610.71 Million |
| Inventory | $35.67 Million |
| Accounts Receivable | $199.98 Million |
| Assets | $1.84 Billion |
| Fixed Assets | $63.17 Million |
| Wages | $46.21 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||